AstraZeneca agreed to invest $2.0 billion in newly issued Summit Therapeutics convertible preferred equity and to test Summit’s ivonescimab with AstraZeneca antibody-drug conjugates. The initial collaboration pairs ivonescimab, a PD-1/VEGF bispecific originally engineered by…
Merck acquired exclusive worldwide development, manufacturing and commercialization rights to SPR2015 from Shanghai-based SciBrunch Therapeutics. Merck will pay $400 million upfront; total potential consideration, including the upfront, is $2.13 billion. The transaction has closed….
ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million primary shares at $17 each, for approximately $446.3 million in gross proceeds before expenses. Trading began on Nasdaq on September 25 under ADRX,…
Finland-based Kasvu Therapeutics raised a €30 million Series A led by Hadean Ventures, with Tesi, Innovestor and other Finnish science investors participating. Proceeds are intended to take KTX-0141, a small-molecule positive allosteric modulator of…
Roche agreed to pay Atavistik Bio $70 million upfront for a multi-target research collaboration using Atavistik’s AMPS platform to discover allosteric small molecules in cardiovascular, renal and metabolic disease. Atavistik may receive up to…
InnoCare Pharma entered a research collaboration and license agreement with Eli Lilly covering compounds against as many as five undisclosed targets. InnoCare may receive up to $100 million in upfront and near-term payments, approximately…
Ligand committed up to $47 million to AvenCell Therapeutics. Up to $41 million will be provided in exchange for mid-single-digit to low-double-digit royalties on worldwide sales across current and future AvenCell assets, and up…
Basecamp Research announced a $140 million oversubscribed Series C led by S32, with participation from NVIDIA and other investors. It plans to expand its EDEN biological foundation models and advance an in vivo cell…
REGENXBIO disclosed a 23 September settlement with Sarepta, the University of Pennsylvania and Catalent resolving litigation over two patents involving manufacture and sale of Elevidys. Sarepta will pay REGENXBIO $39 million within ten days…
Suzhou-based BoomRay granted Novartis exclusive global rights to an undisclosed preclinical radioligand therapy asset. BoomRay is eligible for up to $900 million including upfront, development, regulatory, and sales payments, plus royalties. The transaction is…
